EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische StudiePragmatische Studie

Brazil-TNT: A Randomized Phase 2 Trial of Neoadjuvant Chemoradiation Followed by FOLFIRINOX Versus Chemoradiation for Stage II/III Rectal Cancer

Diogo Diniz Gomes Bugano, Vanessa Montes Santos, Arinilda Campos-Bragagnoli, Julia Carole Medeiros Melo, Luis Gustavo Capochin Romagnolo, Osmar Barbosa Neto, Icaro Thiago Carvalho, Juliana Karassawa-Helito, Cinthia D Ortega, Cassia Franco Tridente, Lucas Soares Gerbasi, Francisco Tustumi und 9 weitere

Clinical Colorectal Cancer · 2024

DOI: 10.1016/j.clcc.2024.03.003 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical Colorectal Cancer, 2024. Verfasst von Diogo Diniz Gomes Bugano und 20 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Israelita Albert Einstein, São Paulo, Brazil; Hospital Municipal Vila Santa Catarina, São Paulo, Brazil. Electronic address: diogo.gomes@ein…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Rectal Neoplasms, Neoadjuvant Therapy, Oxaliplatin. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Neoadjuvant radiation and oxaliplatin-based systemic therapy (total neoadjuvant therapy-TNT) have been shown to increase response and organ-preservation rates in localized rectal cancer. However, trials have been heterogeneous regarding treatment protocols and few have used a watch-and-wait (WW) approach for complete responders. This trial evaluates if conventional long-term chemoradiation followed by consolidation of FOLFIRINOX increases complete response rates and the number of patients managed by WW. METHODS: This was a pragmatic randomized phase II trial conducted in 2 Cancer Centers in Brazil that included patients with T3+ or N+ rectal adenocarcinoma. After completing a long-course 54 Gy chemoradiation with capecitabine patients were randomized 1:1 to 4 cycles of mFOLFIRINOX (Oxaliplatin 85, irinotecan 150, 5-FU 2400)-TNT-arm-or to the control arm, that did not include further neoadjuvant treatment. All patients were re-staged with dedicated pelvic magnetic resonance imaging and sigmoidoscopy 12 weeks after the end of radiation. Patients with a clinical complete response were followed using a WW protocol. The primary endpoint was complete response: clinical complete response (cCR) or pathological response (pCR). RESULTS: Between April 2021 and June 2023, 55 patients were randomized to TNT and 53 to the control arm. Tumors were 74% stage 3, median distance from the anal verge was 6 cm, 63% had an at-risk circumferential margin, and 33% an involved sphincter. The rates of cCR + pCR were (31%) for TNT versus (17%) for controls (odds ratio 2.19, CI 95% 0.8-6.22 P = .091) and rates of WW were 16% and 9% (P = ns). Median follow-up was 8.1 months and recurrence rates were 16% versus 21% for TNT and controls (P = ns). CONCLUSIONS: TNT with consolidation FOLFIRINOX is feasible and has high response rates, consistent with the current literature for TNT. This trial was supported by a grant from the Brazilian Government (PROADI-SUS - NUP 25000.164382/2020-81).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsRectal NeoplasmsNeoadjuvant TherapyOxaliplatinFluorouracilIrinotecanLeucovorinNeoplasm StagingHumansMiddle AgedMaleFemaleAgedBrazilAdultChemoradiotherapyAdenocarcinomaWatchful WaitingTreatment OutcomeChemoradiotherapy, AdjuvantCapecitabineFollow-Up Studies

Stichwörter der Autor:innen

ChemoradiotherapyColorectal surgeryFOLFIRINOXNeoadjuvant therapyRectal neoplasms

Substanzen

OxaliplatinFluorouracilIrinotecanfolfirinoxLeucovorinCapecitabine

Autor:innen und Institutionen

  • Hospital Israelita Albert Einstein, São Paulo, Brazil; Hospital Municipal Vila Santa Catarina, São Paulo, Brazil. Electronic address: diogo.gomes@einstein.br.
  • Hospital Israelita Albert Einstein, São Paulo, Brazil; Hospital Municipal Vila Santa Catarina, São Paulo, Brazil.
  • Hospital do Cancer de Barretos, Barretos, Brazil.
  • Hospital Municipal Vila Santa Catarina, São Paulo, Brazil.
  • Hospital Israelita Albert Einstein, São Paulo, Brazil.

Zitieren

APA

Bugano, D. D. G., Santos, V. M., Campos-Bragagnoli, A., Melo, J. C. M., Romagnolo, L. G. C., Barbosa Neto, O., Carvalho, I. T., Karassawa-Helito, J., Ortega, C. D., Tridente, C. F., Gerbasi, L. S., Tustumi, F., Giovani Blasi, P. B., Novaes Figueiredo de Araujo, M., Pandini, R. V., Seid, V. E., Portilho, A. S., Buosso, A., Rolla, F., …, & Araujo, S. E. A. (2024). Brazil-TNT: A Randomized Phase 2 Trial of Neoadjuvant Chemoradiation Followed by FOLFIRINOX Versus Chemoradiation for Stage II/III Rectal Cancer. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2024.03.003

Vancouver

Bugano DDG, Santos VM, Campos-Bragagnoli A, Melo JCM, Romagnolo LGC, Barbosa Neto O, et al. Brazil-TNT: A Randomized Phase 2 Trial of Neoadjuvant Chemoradiation Followed by FOLFIRINOX Versus Chemoradiation for Stage II/III Rectal Cancer. Clinical Colorectal Cancer. 2024. doi:10.1016/j.clcc.2024.03.003

BibTeX
@article{Bugano2024,
  author = {Bugano, Diogo Diniz Gomes and Santos, Vanessa Montes and Campos-Bragagnoli, Arinilda and Melo, Julia Carole Medeiros and Romagnolo, Luis Gustavo Capochin and Barbosa Neto, Osmar and Carvalho, Icaro Thiago and Karassawa-Helito, Juliana and Ortega, Cinthia D and Tridente, Cassia Franco and Gerbasi, Lucas Soares and Tustumi, Francisco and Giovani Blasi, Poliana Bergamaschine and Novaes Figueiredo de Araujo, Marleny and Pandini, Rafael Vaz and Seid, Victor Edmond and Portilho, Ana Sarah and Buosso, Albert and Rolla, Fabiana and Schettino, Guilherme de Paula Pinto and Araujo, Sergio Eduardo Alonso},
  title = {Brazil-TNT: A Randomized Phase 2 Trial of Neoadjuvant Chemoradiation Followed by FOLFIRINOX Versus Chemoradiation for Stage II/III Rectal Cancer},
  journal = {Clinical Colorectal Cancer},
  year = {2024},
  doi = {10.1016/j.clcc.2024.03.003}
}
Kostenlos starten →